Backenroth Samuel 4
4 · NeuBase Therapeutics, Inc. · Filed Dec 30, 2020
Insider Transaction Report
Form 4
Backenroth Samuel
CEO & VP of Bus. Development
Transactions
- Award
Stock option (right to buy)
2020-12-29+41,915→ 41,915 totalExercise: $6.92Exp: 2030-12-29→ Common Stock (41,915 underlying)
Footnotes (1)
- [F1]25% of the total shares shall vest on the first anniversary of December 29, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months.